公开(公告)号：US20070104780A1

公开(公告)日：2007-05-10

申请号：US11552344

申请日：2006-10-24

Applicant: John Lipari ,  Didier Lefebvre ,  Tzuchi Ju ,  Kennan Marsh ,  Geoff Zhang ,  Jayanthy Jayanth ,  Chetan Pujara ,  Howard Cheskin ,  Vitomir Vucenovic ,  Ping Tong

Inventor： John Lipari ,  Didier Lefebvre ,  Tzuchi Ju ,  Kennan Marsh ,  Geoff Zhang ,  Jayanthy Jayanth ,  Chetan Pujara ,  Howard Cheskin ,  Vitomir Vucenovic ,  Ping Tong

IPC: A61K31/506 ,  A61K31/501 ,  A61K31/497 ,  A61K31/4439 ,  A61K31/425 ,  A61K31/42 ,  A61K31/416 ,  A61K9/64

CPC classification number: A61K9/10 ,  A61K9/0056 ,  A61K9/0095 ,  A61K9/107 ,  A61K9/48 ,  A61K31/416 ,  A61K31/42 ,  A61K31/423 ,  A61K31/425 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/497 ,  A61K31/501 ,  A61K31/503 ,  A61K31/506 ,  A61K31/517 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/24 ,  A61K47/44

Abstract: A pharmaceutical composition comprises a drug-carrier system having a small-molecule drug of low water solubility, e.g. N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea (ABT-869), and (+)-1-(5-tert-butyl-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102), in solution in a substantially non-aqueous carrier that comprises at least one phospholipid and a pharmaceutically acceptable solubilizing agent. The drug-carrier system, when mixed with an aqueous phase, typically forms a non-gelling, substantially non-transparent liquid dispersion. The composition is suitable for administration by a suitable route, e.g. orally, to a subject in need thereof.

Abstract translation: 药物组合物包含具有低水溶性的小分子药物的药物 - 载体体系，例如。 N- [4-（3-氨基-1H-吲唑-4-基）苯基] -N' - （2-氟-5-甲基苯基）脲（ABT-869）和（+） - - 叔丁基-1-基）-3-（1H-吲唑-4-基） - 脲（ABT-102）在基本上非水性载体中的溶液中，其包含至少一种磷脂和药学上可接受的增溶剂 。 当与水相混合时，药物载体体系通常形成非凝胶化的基本不透明的液体分散体。 该组合物适合通过合适途径施用，例如 口服，给有需要的受试者。

公开(公告)号：US20230227463A1

公开(公告)日：2023-07-20

申请号：US18176850

申请日：2023-03-01

Applicant: Ayman Allian ,  Jayanthy Jayanth ,  Mohamed-Eslam F. Mohamed ,  Mathew M. Mulhern ,  Fredrik Lars Nordstrom ,  Ahmed A. Othman ,  Michael J. Rozema ,  Lakshmi Bhagavatula ,  Patrick J. Marroum ,  Peter T. Mayer ,  Ahmad Y. Sheikh ,  Thomas B. Borchardt ,  Ben Klünder

Inventor： Ayman Allian ,  Jayanthy Jayanth ,  Mohamed-Eslam F. Mohamed ,  Mathew M. Mulhern ,  Fredrik Lars Nordstrom ,  Ahmed A. Othman ,  Michael J. Rozema ,  Lakshmi Bhagavatula ,  Patrick J. Marroum ,  Peter T. Mayer ,  Ahmad Y. Sheikh ,  Thomas B. Borchardt ,  Ben Klünder

IPC: C07D487/14 ,  A61K9/00 ,  A61K47/12 ,  A61K47/38 ,  A61K31/4985

CPC classification number: C07D487/14 ,  A61K9/0053 ,  A61K47/12 ,  A61K47/38 ,  A61K31/4985 ,  C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).

公开(公告)号：US20050079221A1

公开(公告)日：2005-04-14

申请号：US10683747

申请日：2003-10-10

Applicant: Pieter Groenewoud ,  John Facemire ,  Jayanthy Jayanth

Inventor： Pieter Groenewoud ,  John Facemire ,  Jayanthy Jayanth

IPC: A61K9/16 ,  A61K45/06 ,  A61K9/14 ,  A61K9/20 ,  D04H1/00

CPC classification number: A61K45/06 ,  A61K9/1652

Abstract: A pharmaceutical composition in a plurality of units includes ibuprofen, in a concentration of between 10% and 84%, by weight, of each of the plurality of units, and a narcotic analgesic, of which each of the plurality of units includes between 1 mg to 60 mg of the narcotic analgesic. Other ingredients include: a disintegrant, in a concentration of between 0.25% to 15% by weight of each of the plurality of units; a filler, in a concentration of between 2% to 90% by weight of each of the plurality of units; and a binder, in a concentration of between 0.25% to 20% by weight of each of the plurality of units.

Abstract translation: 多个单位的药物组合物包括浓度为多个单位中的每一个的10重量％至84重量％的布洛芬和麻醉止痛剂，其中多个单位中的每一个包含1mg 至60mg麻醉止痛剂。 其他成分包括：崩解剂，其浓度为多个单元中的每一个的0.25重量％至15重量％; 填充剂，其浓度为所述多个单元中的每一个的2重量％至90重量％; 和粘合剂，其浓度为多个单元中的每一个的0.25重量％至20重量％。